摘要
目的探讨抗突变型瓜氨酸波形蛋白(MCV)抗体滴度与类风湿关节炎(RA)患者系统受累和疾病复发的相关性。方法选取RA患者121例作为RA组,体检健康者60例作为对照组,比较两组的抗MCV抗体滴度,以及不同临床特征RA患者的抗MCV抗体滴度。根据RA患者的治疗效果,分为缓解组和未缓解组,比较两组不同治疗时间的抗MCV抗体滴度。记录缓解组患者随访中的复发情况,采用Spearman相关分析患者治疗前、治疗3个月和治疗6个月时抗MCV抗体滴度与复发的相关性。结果RA组抗MCV抗体滴度明显高于对照组(P<0.05)。RA患者抗MCV抗体滴度与关节受累程度、关节腔积液、疾病活动性评分(DAS28评分)以及肺间质病变有关(P<0.05)。受试者工作特征(ROC)曲线分析结果显示,抗MCV抗体预测RA患者肺间质病变的曲线下面积为0.770,灵敏度为89.60%,特异度为61.60%。治疗3个月和6个月时,缓解组的抗MCV抗体滴度低于治疗前,差异有统计学意义(P<0.05)。Spearman相关分析结果提示,治疗前、治疗3个月和治疗6个月时患者的抗MCV抗体滴度与复发均无相关性(P>0.05)。结论抗MCV抗体滴度与RA患者DAS28评分、关节受累程度、关节腔积液及肺间质病变有关,与复发无关,抗MCV抗体可作为RA患者肺间质病变预测和疗效评估的有效指标。
Objective To investigate the correlation between anti-mutant citrulline vimentin(MCV)antibody titer with systemic involvement and recurrence in the patients with rheumatoid arthritis(RA).Methods A total of 121 patients with RA were selected as the RA group,and 60 healthy subjects undergoing physical examination served as the control group.The anti-MCV antibody titers were compared between the two groups,and the anti-MCV antibody titers were compared among the RA patients with different clinical characteristics.According to the treatment effect in RA patients,they were divided into the remission group and non-remission group,and the anti-MCV antibody titers in the two groups were compared among different treatment time.The recurrence in the remission group was recorded during follow-up,and the Spearman correlation was adopted to analyze the correlation between the anti-MCV antibody titers and recurrence before treatment,in 3 months and 6 months of treatment.Results The anti-MCV antibody titers in the RA group was significantly higher than that in the control group(P<0.05).The anti-MCV antibody titers in RA patients was correlated with the degree of joint involvement,joint cavity effusion,DAS28 score and pulmonary interstitial lesion(P<0.05).The receiver operating characteristic(ROC)curve analysis results showed that the area under the curve of anti-MCV antibody in predicting pulmonary interstitial lesions in RA patients was 0.770,the sensitivity was 89.60%,and the specificity was 61.60%.At 3 and 6 months of treatment,the anti-MCV antibody titers in the remission group were lower than those before treatment,and the differences were statistically significant(P<0.05).The Spearman correlation analysis results showed that there was no correlation between the anti-MCV antibody titers before treatment,in 3 months and 6 months of treatment with the recurrence(P>0.05).Conclusion The anti-MCV antibody titer is correlated with the DAS28 score,the degree of joint involvement,joint cavity effusion and pulmonary interstitial lesion in RA patients,but has no relation with recurrence.The anti-MCV antibody could be used as an effective indicator for predicting pulmonary interstitial lesion and evaluating the treatment efficacy in RA patients.
作者
赵浩宇
ZHAO Haoyu(Department of Hematology and Rheumatology,Hanzhong Municipal Central Hospital,Hanzhong,Shaanxi 723000,China)
出处
《检验医学与临床》
CAS
2022年第11期1518-1521,共4页
Laboratory Medicine and Clinic
关键词
抗突变型瓜氨酸波形蛋白抗体
关节受累
类风湿关节炎
肺间质病变
复发
anti-mutant citrulline vimentin antibody
joint involvement
rheumatoid arthritis
interstitial lung lesion
recurrence
作者简介
赵浩宇,女,主管技师,主要从事血液病、风湿病实验室诊断研究。
